Abstract
Background: Fazarabine is a novel nucleoside with broad spectrum pre-clinical activity and was chosen for study in patients with incurable non-small cell carcinoma of the lung. The expenses associated with investigational treatment have been assumed to be more than what would occur with conventional therapy, however, data are limited. Methods: Twenty-three patients with metastatic non-small cell lung cancer were treated with fazarabine. Fazarabine was administered as a 72 hour continuous infusion at 2.0 mg/M2/hour. A cost analysis of treatment was calculated for patients treated in Springfield, MO. Results: There were no responses (0%, 95% confidence interval = 0-15%) and median survival was 8 months. An analysis of the cost of treatment in the 4 patients treated in Springfield, MO, was compared to the costs of treatment with 4 cycles of cisplatinum and etoposide. There were no significant differences in costs for patients treated with the investigational agent as compared with conventional chemotherapy. Conclusions: Fazarabine has no demonstrable activity in patients with metastatic non-small cell carcinoma of the lung. Treatment with this agent in an investigational setting was no more expensive than treatment with conventional chemotherapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 67-71 |
| Number of pages | 5 |
| Journal | Investigational New Drugs |
| Volume | 13 |
| Issue number | 1 |
| State | Published - 1995 |
| Externally published | Yes |
Fingerprint
Keywords
- Cost analysis
- Fazarabine
- Lung neoplasms
- Nucleosides
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology
Cite this
Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung : A Southwest Oncology Group Study. / Williamson, S. K.; Crowley, J. J.; Livingston, Robert B; Panella, T. J.; Goodwin, J. W.
In: Investigational New Drugs, Vol. 13, No. 1, 1995, p. 67-71.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung
T2 - A Southwest Oncology Group Study
AU - Williamson, S. K.
AU - Crowley, J. J.
AU - Livingston, Robert B
AU - Panella, T. J.
AU - Goodwin, J. W.
PY - 1995
Y1 - 1995
N2 - Background: Fazarabine is a novel nucleoside with broad spectrum pre-clinical activity and was chosen for study in patients with incurable non-small cell carcinoma of the lung. The expenses associated with investigational treatment have been assumed to be more than what would occur with conventional therapy, however, data are limited. Methods: Twenty-three patients with metastatic non-small cell lung cancer were treated with fazarabine. Fazarabine was administered as a 72 hour continuous infusion at 2.0 mg/M2/hour. A cost analysis of treatment was calculated for patients treated in Springfield, MO. Results: There were no responses (0%, 95% confidence interval = 0-15%) and median survival was 8 months. An analysis of the cost of treatment in the 4 patients treated in Springfield, MO, was compared to the costs of treatment with 4 cycles of cisplatinum and etoposide. There were no significant differences in costs for patients treated with the investigational agent as compared with conventional chemotherapy. Conclusions: Fazarabine has no demonstrable activity in patients with metastatic non-small cell carcinoma of the lung. Treatment with this agent in an investigational setting was no more expensive than treatment with conventional chemotherapy.
AB - Background: Fazarabine is a novel nucleoside with broad spectrum pre-clinical activity and was chosen for study in patients with incurable non-small cell carcinoma of the lung. The expenses associated with investigational treatment have been assumed to be more than what would occur with conventional therapy, however, data are limited. Methods: Twenty-three patients with metastatic non-small cell lung cancer were treated with fazarabine. Fazarabine was administered as a 72 hour continuous infusion at 2.0 mg/M2/hour. A cost analysis of treatment was calculated for patients treated in Springfield, MO. Results: There were no responses (0%, 95% confidence interval = 0-15%) and median survival was 8 months. An analysis of the cost of treatment in the 4 patients treated in Springfield, MO, was compared to the costs of treatment with 4 cycles of cisplatinum and etoposide. There were no significant differences in costs for patients treated with the investigational agent as compared with conventional chemotherapy. Conclusions: Fazarabine has no demonstrable activity in patients with metastatic non-small cell carcinoma of the lung. Treatment with this agent in an investigational setting was no more expensive than treatment with conventional chemotherapy.
KW - Cost analysis
KW - Fazarabine
KW - Lung neoplasms
KW - Nucleosides
UR - http://www.scopus.com/inward/record.url?scp=0029157676&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029157676&partnerID=8YFLogxK
M3 - Article
C2 - 7499111
AN - SCOPUS:0029157676
VL - 13
SP - 67
EP - 71
JO - Investigational New Drugs
JF - Investigational New Drugs
SN - 0167-6997
IS - 1
ER -